2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, APL, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5173 A prospective clinical study of venetoclax single-agent for the maintenance treatment of elderly patients with acute myeloid leukemia in first complete remission

Yayi Liu, Lei Fan, MD2, Jianyong Li, MD3, Qian Sun, MD4, Yu Zhu, MD5, Wenjie Liu, MD6, Ming Hong, MD7
1 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
2 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
3 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
4 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
5 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
6 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
7 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China

Patients with acute myeloid leukemia (AML) remain at high risk of relapse after achieving complete remission (CR) or CR with incomplete hematologic recovery (CRi), highlighting the need for effective, practical post-remission maintenance strategies. Oral azaciditine (AZA) (CC-486) and venetoclax (VEN) plus AZA maintenance has shown improvements in overall survival (OS) and relapse-free survival (RFS) in older patients with AML, whereas oral VEN as maintenance therapy may be more feasible.

 

We conducted a prospective multicenter single-arm study (NCT05909293) enrolling patients with AML aged 60–85 years who achieved CR/CRi after 1–2 induction cycles, received ≥4 consolidation cycles, and were unsuitable for or declined allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients received orally VEN 400 mg on days 1-14 in 28-day cycles. Dose and schedule adjustments were allowed for patients receiving concomitant CYP3A inhibitors, experiencing treatment-related toxicities, or presenting with other clinical indications requiring intervention. A total of 12 maintenance cycles were scheduled, with treatment extension permitted for patients demonstrating sustained clinical benefit and acceptable tolerability. Patients with FLT3 and IDH1 mutations could receive corresponding targeted agents. Primary endpoints were OS and RFS. Secondary endpoints included measurable residual disease (MRD) dynamics and adverse events (AEs).

 

As of July 9, 2026, 42 patients were enrolled. The full cohort comprised 29 (69.0%) males and 13 (31.0%) females, with a median age of 68 years (range, 60-83). According to the 2022 European LeukemiaNet (ELN) risk classification, 22 (52.4%), 10 (23.8%), and 10 (23.8%) patients harbored favorable-, intermediate-, and adverse-risk disease, respectively. All patients underwent low-intensity induction of whom 36 (85.7%) were treated with a VEN-based regimen. Prior to maintenance therapy, 41 patients (97.6%) achieved multiparameter flow cytometry-defined MRD negativity, with a threshold of <0.1%.Thirty patients (71.4%) received single-agent VEN, while 12 patients (28.6%) were treated with VEN combined with an FLT3 or IDH1 inhibitors to target actionable molecular alterations.

 

The median number of maintenance cycles was 12 (IQR 5-18). At the time of data cutoff (median follow-up: 32.8 months), 22 patients (52.4%) finished the planned treatment course, while 12 patients (28.6%) were still receiving active therapy. Treatment discontinuation occurred in 7 patients (16.7%) due to disease relapse, and 1 patient (2.4%) stopped therapy as a result of death. The median OS and RFS were not reached. The 12-, 24-, and 36-month OS rates calculated from the time of diagnosis were 100%, 97.3% (95% CI, 82.3%-99.6%), and 94.1% (95% CI, 78.1%-98.5%), respectively. The corresponding RFS rates from first CR/CRi were 95.2% (95% CI, 82.1%-98.8%), 80.7% (95% CI, 63.4%-90.4%), and 76.0% (95% CI, 56.5%-87.6%). Eight patients experienced disease relapse during follow-up: 2 with favorable-risk cytogenetics, 3 with intermediate-risk, and 3 with adverse-risk disease. The observed relapse rates across these risk subgroups were 9.1%, 30.0%, and 30.0%, respectively. Five of the relapsed patients died. Three patients underwent allo-HSCT following disease relapse and remained alive with post-transplant follow-up durations of 27, 22, and 1 months, respectively.

 

Of the 41 patients who achieved MRD negativity prior to maintenance therapy, 32 sustained MRD negativity, while 9 developed MRD positivity; 8 of these 9 patients subsequently experienced morphologic disease relapse. One patient with MRD negativity at the pre-maintenance assessment attained undetectable MRD during maintenance therapy. Only one patient developed a grade 3 AE of decreased neutrophil count. Two patients discontinued VEN due to persistent or recurrent neutropenia, with one grade 1 and one grade 2 case. No treatment-related deaths were observed.

 

Maintenance therapy with single-agent VEN exhibited favorable feasibility, promising survival endpoints, and a low rate of high-grade toxicities among older patients with AML. Owing to the limited sample size, absence of a control arm, and coadministration of targeted agents in a subset of participants, these results warrant further validation in larger cohorts with extended follow-up and randomized controlled trials.

Wenjie Liu, MD: No relevant conflicts of interest to declare.